Abstract
Introduction: Semaglutide is an antidiabetic drug analogous to human GLP-1 (glucagon-like peptide), a class of drugs that has recently gained prominence thanks to its good results in clinical trials, however, the retention of data on its effects on diseases Chronic and acute cardiovascular and renal disorders limit its use to the general public. Acute kidney disease affects approximately …